VaramirStart free · no cardSign in
ACRS as of Oct 31 · 01:54 ET
ACRSNasdaqPharmaceutical Preparations

Aclaris Therapeutics, Inc. · Brief

Next report

117 days

Feb 25 · before openest.Q4 FY26
Earnings

Expected move

Inputs

Implied vs realized

8 reportsHistory
0 of 8≥ implied
avg implied
±25.3%
avg realized
±3.1%
Feb 27 '25±19.7%▼−7.14%×0.36
May 8 '25±50.7%▲+4.80%×0.09
Aug 7 '25±30.2%▲+1.29%×0.04
Q3 FY25±22.0%▲+0.44%×0.02
Q1 FY26±16.7%▼−5.44%×0.32
May 7 '26±11.5%▲+1.67%×0.15
Q2 FY26±18.4%▼−4.25%×0.23
Oct 27 '26±33.1%0.00%×0.00
quarterimplied−55%0+55%realized×
Oct '26±33.1%0.00%×0.00
Q2 FY26±18.4%▼−4.25%×0.23
May '26±11.5%▲+1.67%×0.15
Q1 FY26±16.7%▼−5.44%×0.32
Q3 FY25±22.0%▲+0.44%×0.02
Aug '25±30.2%▲+1.29%×0.04
2 older reports
May '25±50.7%▲+4.80%×0.09
Feb '25±19.7%▼−7.14%×0.36
Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Bull & bear

Feb 25 report · est.

—

Linked exposure

ACRS report session

No linked exposure.

Latest changes

30 daysAll changes
Oct 278-KMaterial agreement: underwriting agreement with Leerink Partners LLC.Source
Oct 26impliedImplied move: ±33.1% into Oct 27 earnings (Oct 26 close).Source
Oct 22impliedImplied move: ±33.9% into Nov 5 earnings (Oct 22 close).Source

Your note

privateThesis 0 · Decisions 0 · Observations 0

No thesis.